1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Anhui Huaheng Biotechnology Co., Ltd.

Anhui Huaheng Biotechnology Co., Ltd.

688639.SS
Anhui Huaheng Biotechnology Co., Ltd.CN flagShanghai Stock Exchange
15.99
CNY
-0.42
- -
4.00BMarket Cap
Anhui Huaheng Biotechnology Co., Ltd.
688639.SS
(Shanghai Stock Exchange)

Recent

price

15.99

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
8.25
3.4
2.65
3.24
2.27
2.49
2.88
2.87
4.59
6.24
8.46
9.42
11.45
10.38
Revenue per Share
- -
0.62
0.35
0.45
0.64
0.39
0.45
0.74
0.71
0.81
1.41
1.96
0.82
0.53
0.61
Basic EPS, GAAP
- -
0.89
0.17
-0.57
-0.04
0.34
0.15
0.59
0.22
-0.41
-0.43
-4.22
-3.13
-2.13
-2.9
Free Cash Flow per Basic Share
- -
0.3
0.3
0.37
0.08
0.19
0.03
0.44
0.02
0.18
0.26
0.48
0.79
0.44
0.72
Dividend per Share
- -
0.45
0.24
0.58
1.19
0.87
1.31
1.81
2.51
2.75
3.65
5.29
5.75
5.56
5.41
Book Value per Share
- -
0.29
0.61
0.96
1.48
1.06
1.67
1.91
2.64
5.47
6.19
7.59
10.47
9.93
9.65
Tangible Book Value per Share
- -
21
66
96
96
168
169
170
170
208
227
229
231
250
255
Basic Weighted Avg Shares
87
173
225
253
311
383
421
491
487
954
1,419
1,938
2,178
2,862
2,651
Sales/Revenue/Turnover
-0.54
10.11
10.13
18.7
22.38
21.73
21.03
30.43
29.26
19.41
23.29
26.56
10.25
6.58
7.72
Operating Margin (%)
3
5
8
8
12
21
24
33
35
48
59
99
139
215
- -
Depreciation Expense
-4
13
23
43
62
65
76
126
121
168
320
449
190
132
155
Net Income, GAAP
- -
7.51
11.35
14.14
15.57
12.48
12.76
13.31
13.46
11.82
6.89
11.79
8.36
1.35
6.28
Effective Tax Rate (%)
-4.38
7.5
10.22
16.89
19.84
16.96
17.94
25.72
24.85
17.63
22.56
23.17
8.7
4.63
5.84
Profit Margin (%)
-25
-63
-30
18
8
3
37
54
100
670
474
-626
-252
125
124
Working Capital
- -
- -
13
60
40
30
15
- -
- -
- -
- -
305
638
1,572
1,161
LT Debt
8
20
54
114
176
211
313
369
490
1,183
1,482
1,826
2,558
2,632
2,618
Total Equity
- -
20.44
19.49
23.1
22.35
24.36
21.8
30.51
24.82
18.5
22.06
19.42
5.67
4.22
4.88
Return on Invested Capital (%)
- -
18.25
30.17
34.91
31.16
30.12
28.71
37.4
28.97
31.63
42.84
27.37
8.6
5.85
6.79
Return on Capital (%)
- -
150.88
183.5
120.21
72.7
49.62
40.9
47.73
33.05
33.76
45.69
43.98
14.91
9.74
11.88
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
908
674
551
LT Borrowings
638
957
1,161
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
250
250
250
Market Capitalization
7,967
7,547
8,099

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,352
1,444
1,453
Cash, Cash Equivalents & STI
423
418
379
Accounts Receivable, Net
284
308
308
Inventories
407
479
509
Total Current Liabilities
1,604
1,404
1,328
Payables & Accruals
- -
- -
- -
ST Debt
908
674
551
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.57%
46.6%
2.87%
Free Cash Flow
-102.3%
102.62%
-26.47%
Net Income, GAAP
21.05%
16.31%
-30.13%
Sales/Revenue/Turnover
29.65%
44.98%
31.4%
Total Cash Common Dividend
292.58%
276.95%
-39.58%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
501
515
523
639
2,178
2025
687
802
668
- -
2,862
2026
771
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.35
- -
- -
- -
0.82
2025
0.2
- -
- -
- -
0.53
2026
0.17
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
- -
- -
- -
0.79
2025
0.04
- -
- -
- -
0.44
2026
0.06
- -
- -
- -
- -
Similar Companies
Gelesis Holdings, Inc. (GLS-WT)
Polus BioPharm Inc. (007630.KS)
Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ)
Adicet Bio, Inc. (0HX7.L)
D&D Pharmatech (347850.KQ)
Oncopeptides AB (publ) (ONCO.ST)
Business
Anhui Huaheng Biotechnology Co., Ltd. (688639.SH) engages in the research, development, production and sale of amino acids, vitamins, bio-based intermediates and monomers utilizing synthetic biotechnology. The company offers alanine series products including L-alanine, DL-alanine and beta-alanine; valine products such as L-valine; vitamin derivatives like D-pantothenate calcium and D-pantothenol; alpha-arbutin; malic acid; as well as branded solutions encompassing AH Synova bio-based material monomers, AHB pharmaceutical intermediates and bio-based chemicals, AH BIOSUS amino acids and peptides, VITAROSUS vitamins, AHB flavor agents, BIOPURENOL high-performance humectants and multifunctional solvents, BIOBLANCA whitening actives, BIOAGRI fertilizer enhancers and biostimulants; these serve intermediates, animal nutrition, personal care, plant nutrition, functional foods and human nutrition sectors. Founded on April 13, 2005 and headquartered at 32 Fengjin Road, Shuangfeng Industrial Zone, Hefei, Anhui Province, China, the company operates globally across more than 80 countries and regions, serving over 768 customers including Fortune 500 firms like BASF. In recent developments, Anhui Huaheng Biotechnology signed a strategic cooperation agreement with BASF Agricultural Solutions in May 2024 to jointly develop biostimulants and establish a Plant Nutrition Application R&D Institute for crop yield enhancement and resilience; achieved key breakthroughs in new products including 1,3-propanediol, succinic acid, tryptophan and arginine in 2024; and submitted an application in September 2025 for an H-share listing on the Hong Kong Stock Exchange, with Huatai International as sponsor, aiming to expand its dual-listing structure following its 2021 STAR Market debut.